Biocompatibles first-half sales quadruple:
This article was originally published in Clinica
In the first half of the year, UK-based Biocompatibles quadrupled its sales compared with the previous year. Turnover was £1.7 million ($2.6 million), up from £415,000, largely due to the inclusion of £1.4 million in sales from US subsidiary Lombard Lenses which was acquired in September 1994. Net loss rose to £3.7 million from £1 million, which Biocompatibles attributes to the expansion of activities, particularly the commercial development of the eye care and cardiovascular divisions. At its April float on the London market, Biocompatibles raised £17.5 million gross.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.